MX2023005098A - Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central. - Google Patents

Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.

Info

Publication number
MX2023005098A
MX2023005098A MX2023005098A MX2023005098A MX2023005098A MX 2023005098 A MX2023005098 A MX 2023005098A MX 2023005098 A MX2023005098 A MX 2023005098A MX 2023005098 A MX2023005098 A MX 2023005098A MX 2023005098 A MX2023005098 A MX 2023005098A
Authority
MX
Mexico
Prior art keywords
sup
methods
compositions
cns disorders
treating cns
Prior art date
Application number
MX2023005098A
Other languages
English (en)
Inventor
Francesco G Salituro
Albert Jean Robichaud
Boyd L Harrison
Daniel La
Maria Jesus Blanco-Pillado
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2023005098A publication Critical patent/MX2023005098A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003Androstane derivatives
    • C07J1/0011Androstane derivatives substituted in position 17 by a keto group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J13/00Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005Ketals
    • C07J21/008Ketals at position 17
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring

Abstract

Compuestos de la Fórmula (I-I): (ver Fórmula) (I-X) y sus sales farmacéuticamente aceptables, donde p, R1, R3a, R2a, R11a, R11b, R6a, y R6b tienen los valores que se definen en la memoria descriptiva. Composiciones farmacéuticas que comprenden un compuesto de Fórmula (I-X) y usos de los compuestos, por ejemplo en el tratamiento de trastornos relacionados con el sistema nervioso central.
MX2023005098A 2017-12-22 2020-07-13 Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central. MX2023005098A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762610069P 2017-12-22 2017-12-22
US201762611983P 2017-12-29 2017-12-29
US201862620095P 2018-01-22 2018-01-22
US201862722781P 2018-08-24 2018-08-24
US201862734718P 2018-09-21 2018-09-21

Publications (1)

Publication Number Publication Date
MX2023005098A true MX2023005098A (es) 2023-05-24

Family

ID=65234663

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020006599A MX2020006599A (es) 2017-12-22 2018-12-21 Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
MX2023005099A MX2023005099A (es) 2017-12-22 2020-07-13 Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
MX2023005098A MX2023005098A (es) 2017-12-22 2020-07-13 Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2020006599A MX2020006599A (es) 2017-12-22 2018-12-21 Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
MX2023005099A MX2023005099A (es) 2017-12-22 2020-07-13 Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.

Country Status (12)

Country Link
US (1) US20210101928A1 (es)
EP (1) EP3728284A1 (es)
JP (2) JP7382326B2 (es)
KR (1) KR20200104350A (es)
CN (2) CN117946202A (es)
AU (2) AU2018388408B2 (es)
BR (1) BR112020012712A8 (es)
CA (1) CA3086299A1 (es)
IL (2) IL310454A (es)
MA (1) MA51315A (es)
MX (3) MX2020006599A (es)
WO (1) WO2019126741A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112472814A (zh) 2012-01-23 2021-03-12 萨奇治疗股份有限公司 神经活性类固醇制剂和治疗中枢神经系统障碍的方法
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
HUE049014T2 (hu) 2014-11-27 2020-09-28 Sage Therapeutics Inc Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére
JOP20190022B1 (ar) 2016-08-23 2023-03-28 Sage Therapeutics Inc ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
CA3115805A1 (en) 2018-10-12 2020-04-16 Sage Therapeutics, Inc. Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
JOP20210293A1 (ar) 2019-05-31 2023-01-30 Sage Therapeutics Inc ستيرويدات ذات فعالية عصبية وتركيبات منها
JP2022543576A (ja) * 2019-08-07 2022-10-13 上▲海▼翰森生物医▲薬▼科技有限公司 ステロイド誘導体調節因子の塩及び結晶形態
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
PE20221911A1 (es) 2020-03-25 2022-12-23 Sage Therapeutics Inc Uso de agentes para el tratamiento de condiciones respiratorias
EP4172171A1 (en) 2020-06-24 2023-05-03 Sage Therapeutics, Inc. 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3087940A (en) * 1959-02-03 1963-04-30 Advance Growth Capital Corp 19-methyl pregnene derivatives
GB1036418A (en) * 1962-07-09 1966-07-20 Syntex Corp 19-alkyl-steroids and process for their production
DE2438020A1 (de) * 1974-08-05 1976-02-26 Schering Ag 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US20150291654A1 (en) 2011-10-14 2015-10-15 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
US9512170B2 (en) * 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
PT3488852T (pt) 2013-08-23 2021-02-03 Sage Therapeutics Inc Esteroides neuroativos, composições e seus usos
NZ731034A (en) 2014-10-16 2024-02-23 Sage Therapeutics Inc Compositions and methods for treating cns disorders
NZ731095A (en) 2014-10-16 2023-12-22 Sage Therapeutics Inc Compositions and methods for treating cns disorders
US10329320B2 (en) * 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2016164763A1 (en) 2015-04-10 2016-10-13 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Also Published As

Publication number Publication date
AU2024201459A1 (en) 2024-03-21
JP2021506890A (ja) 2021-02-22
IL275562A (en) 2020-08-31
MX2023005099A (es) 2023-05-23
TW201929864A (zh) 2019-08-01
MA51315A (fr) 2020-10-28
JP7382326B2 (ja) 2023-11-16
IL275562B1 (en) 2024-03-01
MX2020006599A (es) 2020-11-06
JP2023113862A (ja) 2023-08-16
CN111770929B (zh) 2023-12-26
CA3086299A1 (en) 2019-06-27
AU2018388408B2 (en) 2023-12-21
CN117946202A (zh) 2024-04-30
IL310454A (en) 2024-03-01
BR112020012712A8 (pt) 2022-03-03
BR112020012712A2 (pt) 2020-11-24
CN111770929A (zh) 2020-10-13
EP3728284A1 (en) 2020-10-28
AU2018388408A1 (en) 2020-07-09
US20210101928A1 (en) 2021-04-08
RU2020123943A (ru) 2022-01-24
WO2019126741A1 (en) 2019-06-27
KR20200104350A (ko) 2020-09-03

Similar Documents

Publication Publication Date Title
MX2023005098A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
MX2023002004A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
SA519401947B1 (ar) مُعدِّل منظم التوصيل عبر الأغشية للتليف الكيسي، تركيبات صيدلية، طرق علاج، وعملية لتحضير المُعدِّل
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
PH12018501920A1 (en) Bromodomain inhibitors
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
MX2020001719A (es) Inhibidores macrocíclicos de mcl-1 y metodos de uso.
PH12017501423A1 (en) Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
PH12017501422A1 (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2021015942A (es) Composiciones y métodos para tratar trastornos del snc.
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
ZA202203108B (en) Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections
MX2019000608A (es) Derivados de panteteina para tratamiento de trastornos neurologicos.